# Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency

> **NCT05222178** · PHASE1 · TERMINATED · sponsor: **Homology Medicines, Inc** · enrollment: 3 (actual)

## Conditions studied

- Phenylketonurias
- PAH Deficiency
- Phenylketonuria

## Interventions

- **DRUG:** HMI-103

## Key facts

- **NCT ID:** NCT05222178
- **Lead sponsor:** Homology Medicines, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-03
- **Primary completion:** 2023-09-14
- **Final completion:** 2023-09-14
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Homology Medicines Inc. has discontinued the development of this program.
- **Last updated:** 2023-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05222178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05222178, "Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05222178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*